Trial Profile
Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2018
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary) ; Erlotinib; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CONFERMER
- 15 Feb 2018 Status changed from recruiting to discontinued.
- 29 Jul 2014 New trial record